Pelthos Therapeutics Inc. (PTHS) Debt Components
- 2026-01-12: Convertible Notes Payable, CurrentUSD (m); Debt Instrument, Fee AmountUSD $663.00K; Debt Instrument, Face AmountUSD (m); Debt Instrument, Annual Principal PaymentUSD (m).
- 2025-06-30: Convertible Notes Payable, CurrentUSD (m); Debt Instrument, Fee AmountUSD (m); Debt Instrument, Face AmountUSD (m); Debt Instrument, Annual Principal PaymentUSD $2.27M.
- 2025-06-23: Convertible Notes Payable, CurrentUSD (m); Debt Instrument, Fee AmountUSD (m); Debt Instrument, Face AmountUSD $163.00K; Debt Instrument, Annual Principal PaymentUSD (m).
- 2025-05-08: Convertible Notes Payable, CurrentUSD (m); Debt Instrument, Fee AmountUSD (m); Debt Instrument, Face AmountUSD $325.00K; Debt Instrument, Annual Principal PaymentUSD (m).
Pelthos Therapeutics Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Debt Instrument, Fee Amount USD | Debt Instrument, Face Amount USD | Debt Instrument, Annual Principal Payment USD | Debt Instrument, Increase, Accrued Interest USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Discount (Premium), Net USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | (m) | $663.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | $2.27M | (m) | $95.10K | $2.17M | (m) |
| 2025-06-23 | (m) | (m) | $163.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-05-08 | (m) | (m) | $325.00K | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | 3 month · $1.82K | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $325.00K | $2.51M | (m) | $135.09K | $2.37M | (m) |
| 2025-02-25 | (m) | (m) | $325.00K | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $2.18M | (m) | $127.43K | $2.05M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $2.21M | (m) | $49.70K | $2.16M | (m) |
| 2024-07-24 | (m) | (m) | $750.00K | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $771.93K | (m) | $21.85K | $750.08K | (m) |
| 2023-09-30 | (m) | (m) | $198.13K | (m) | (m) | (m) | (m) | (m) |
| 2023-04-30 | (m) | (m) | $393.81K | (m) | (m) | (m) | (m) | (m) |
| 2022-12-06 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $75.00K |
| 2022-02-04 | $450.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |